Cargando…

Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients

SIMPLE SUMMARY: The management of patients with non-muscle-invasive, high-grade urothelial carcinoma represents a challenging issue for urologists. The ROL system is a method to evaluate tumor invasion and substage pT1 urothelial carcinoma. In this study, we aimed to confirm in a large and prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Valeri, Marina, Contieri, Roberto, Fasulo, Vittorio, Iuzzolino, Martina, Cieri, Miriam, Elefante, Grazia M., De Carlo, Camilla, Bressan, Alessandra, Saitta, Cesare, Gobbo, Andrea, Avolio, Pier Paolo, Dacrema, Valerio, Lazzeri, Massimo, Taverna, Gianluigi, Terracciano, Luigi M., Hurle, Rodolfo, Colombo, Piergiuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913603/
https://www.ncbi.nlm.nih.gov/pubmed/36765894
http://dx.doi.org/10.3390/cancers15030934
_version_ 1784885467652554752
author Valeri, Marina
Contieri, Roberto
Fasulo, Vittorio
Iuzzolino, Martina
Cieri, Miriam
Elefante, Grazia M.
De Carlo, Camilla
Bressan, Alessandra
Saitta, Cesare
Gobbo, Andrea
Avolio, Pier Paolo
Dacrema, Valerio
Lazzeri, Massimo
Taverna, Gianluigi
Terracciano, Luigi M.
Hurle, Rodolfo
Colombo, Piergiuseppe
author_facet Valeri, Marina
Contieri, Roberto
Fasulo, Vittorio
Iuzzolino, Martina
Cieri, Miriam
Elefante, Grazia M.
De Carlo, Camilla
Bressan, Alessandra
Saitta, Cesare
Gobbo, Andrea
Avolio, Pier Paolo
Dacrema, Valerio
Lazzeri, Massimo
Taverna, Gianluigi
Terracciano, Luigi M.
Hurle, Rodolfo
Colombo, Piergiuseppe
author_sort Valeri, Marina
collection PubMed
description SIMPLE SUMMARY: The management of patients with non-muscle-invasive, high-grade urothelial carcinoma represents a challenging issue for urologists. The ROL system is a method to evaluate tumor invasion and substage pT1 urothelial carcinoma. In this study, we aimed to confirm in a large and prospective series of cases that the ROL system significantly predicts tumor progression. We suggest the application of this system to improve clinical decision-making since it is easy to use, reproducible, and correlates not only with progression but also with recurrence. ABSTRACT: Patients with pT1 high-grade (HG) urothelial carcinoma (UC) and a very high risk of progression might benefit from immediate radical cystectomy (RC), but this option remains controversial. Validation of a standardized method to evaluate the extent of lamina propria (LP) invasion (with recognized prognostic value) in transurethral resection (TURBT) specimens is still needed. The Rete Oncologica Lombarda (ROL) system showed a high predictive value for progression after TURBT in recent retrospective studies. The ROL system was supposed to be validated on a large prospective series of primary urothelial carcinomas from a single institution. From 2016 to 2020, we adopted ROL for all patients with pT1 HG UC on TURBT. We employed a 1.0-mm threshold to stratify tumors in ROL1 and ROL2. A total of 222 pT1 HG UC were analyzed. The median age was 74 years, with a predominance of men (73.8%). ROL was feasible in all cases: 91 cases were ROL1 (41%), and 131 were ROL2 (59%). At a median follow-up of 26.9 months (IQR 13.8–40.6), we registered 81 recurrences and 40 progressions. ROL was a significant predictor of tumor progression in both univariable (HR 3.53; CI 95% 1.56–7.99; p < 0.01) and multivariable (HR 2.88; CI 95% 1.24–6.66; p = 0.01) Cox regression analyses. At Kaplan-Meier estimates, ROL showed a correlation with both PFS (p = 0.0012) and RFS (p = 0.0167). Our results confirmed the strong predictive value of ROL for progression in a large prospective series. We encourage the application of ROL for reporting the extent of LP invasion, substaging T1 HG UC, and improving risk tables for urological decision-making.
format Online
Article
Text
id pubmed-9913603
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99136032023-02-11 Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients Valeri, Marina Contieri, Roberto Fasulo, Vittorio Iuzzolino, Martina Cieri, Miriam Elefante, Grazia M. De Carlo, Camilla Bressan, Alessandra Saitta, Cesare Gobbo, Andrea Avolio, Pier Paolo Dacrema, Valerio Lazzeri, Massimo Taverna, Gianluigi Terracciano, Luigi M. Hurle, Rodolfo Colombo, Piergiuseppe Cancers (Basel) Article SIMPLE SUMMARY: The management of patients with non-muscle-invasive, high-grade urothelial carcinoma represents a challenging issue for urologists. The ROL system is a method to evaluate tumor invasion and substage pT1 urothelial carcinoma. In this study, we aimed to confirm in a large and prospective series of cases that the ROL system significantly predicts tumor progression. We suggest the application of this system to improve clinical decision-making since it is easy to use, reproducible, and correlates not only with progression but also with recurrence. ABSTRACT: Patients with pT1 high-grade (HG) urothelial carcinoma (UC) and a very high risk of progression might benefit from immediate radical cystectomy (RC), but this option remains controversial. Validation of a standardized method to evaluate the extent of lamina propria (LP) invasion (with recognized prognostic value) in transurethral resection (TURBT) specimens is still needed. The Rete Oncologica Lombarda (ROL) system showed a high predictive value for progression after TURBT in recent retrospective studies. The ROL system was supposed to be validated on a large prospective series of primary urothelial carcinomas from a single institution. From 2016 to 2020, we adopted ROL for all patients with pT1 HG UC on TURBT. We employed a 1.0-mm threshold to stratify tumors in ROL1 and ROL2. A total of 222 pT1 HG UC were analyzed. The median age was 74 years, with a predominance of men (73.8%). ROL was feasible in all cases: 91 cases were ROL1 (41%), and 131 were ROL2 (59%). At a median follow-up of 26.9 months (IQR 13.8–40.6), we registered 81 recurrences and 40 progressions. ROL was a significant predictor of tumor progression in both univariable (HR 3.53; CI 95% 1.56–7.99; p < 0.01) and multivariable (HR 2.88; CI 95% 1.24–6.66; p = 0.01) Cox regression analyses. At Kaplan-Meier estimates, ROL showed a correlation with both PFS (p = 0.0012) and RFS (p = 0.0167). Our results confirmed the strong predictive value of ROL for progression in a large prospective series. We encourage the application of ROL for reporting the extent of LP invasion, substaging T1 HG UC, and improving risk tables for urological decision-making. MDPI 2023-02-01 /pmc/articles/PMC9913603/ /pubmed/36765894 http://dx.doi.org/10.3390/cancers15030934 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Valeri, Marina
Contieri, Roberto
Fasulo, Vittorio
Iuzzolino, Martina
Cieri, Miriam
Elefante, Grazia M.
De Carlo, Camilla
Bressan, Alessandra
Saitta, Cesare
Gobbo, Andrea
Avolio, Pier Paolo
Dacrema, Valerio
Lazzeri, Massimo
Taverna, Gianluigi
Terracciano, Luigi M.
Hurle, Rodolfo
Colombo, Piergiuseppe
Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients
title Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients
title_full Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients
title_fullStr Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients
title_full_unstemmed Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients
title_short Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients
title_sort prospective validation of the rol system in substaging pt1 high-grade urothelial carcinoma: results from a mono-institutional confirmatory analysis in bcg treated patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913603/
https://www.ncbi.nlm.nih.gov/pubmed/36765894
http://dx.doi.org/10.3390/cancers15030934
work_keys_str_mv AT valerimarina prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT contieriroberto prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT fasulovittorio prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT iuzzolinomartina prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT cierimiriam prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT elefantegraziam prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT decarlocamilla prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT bressanalessandra prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT saittacesare prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT gobboandrea prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT avoliopierpaolo prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT dacremavalerio prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT lazzerimassimo prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT tavernagianluigi prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT terraccianoluigim prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT hurlerodolfo prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients
AT colombopiergiuseppe prospectivevalidationoftherolsysteminsubstagingpt1highgradeurothelialcarcinomaresultsfromamonoinstitutionalconfirmatoryanalysisinbcgtreatedpatients